Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion type Assertion NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_head.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion description "[Our findings suggest that 1) genetic abnormalities in the coding regions of PP1 alpha, PP1 beta, PP1 gamma, and ISPK-1 are unlikely to be frequently occurring causes of the reduced insulin-stimulated activation of the glycogen synthesis in muscle from the analyzed group of NIDDM patients; 2) the mRNA levels of PP1 alpha, PP1 beta, PP1 gamma, and ISPK-1 are normal in muscle from the NIDDM patients; and 3) putative inherited defects in insulin-stimulated activation of muscle glycogen synthesis in patients with insulin-resistant NIDDM may be located further upstream of ISPK-1 in the insulin action cascade.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_provenance.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion evidence source_evidence_literature NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_provenance.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion SIO_000772 7813820 NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_provenance.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion wasDerivedFrom befree-2016 NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_provenance.
- NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_assertion wasGeneratedBy ECO_0000203 NP1322687.RADIFs0f-3PBQRvF86JGkF_GZ3ZPQw45Qz33T9PXItBq4130_provenance.